Implications of the Cuproptosis Protein SLC31A1 for the Immune Microenvironment and Temozolomide Sensitivity in Glioblastoma
Anticancer Research · 2026
DOI: 10.21873/anticanres.18188 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Daikang Xu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, P.R. China. Hauptthemen laut MEDLINE: Temozolomide, Glioblastoma, Tumor Microenvironment, Brain Neoplasms.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, P.R. China.
- Department of Neurosurgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, P.R. China wangjianpeng@qdu.edu.cn.
Zitieren
APA
Xu, D., DU, G., Sun, J., Zhao, H., Lan, X., & Wang, J. (2026). Implications of the Cuproptosis Protein SLC31A1 for the Immune Microenvironment and Temozolomide Sensitivity in Glioblastoma. Anticancer Research. https://doi.org/10.21873/anticanres.18188
Vancouver
Xu D, DU G, Sun J, Zhao H, Lan X, Wang J. Implications of the Cuproptosis Protein SLC31A1 for the Immune Microenvironment and Temozolomide Sensitivity in Glioblastoma. Anticancer Research. 2026. doi:10.21873/anticanres.18188
BibTeX
@article{Xu2026,
author = {Xu, Daikang and DU, Guangyu and Sun, Jingxian and Zhao, Hai and Lan, Xiaolei and Wang, Jianpeng},
title = {Implications of the Cuproptosis Protein SLC31A1 for the Immune Microenvironment and Temozolomide Sensitivity in Glioblastoma},
journal = {Anticancer Research},
year = {2026},
doi = {10.21873/anticanres.18188}
}
EUVIMED